On September 23, at the 2026 online investor reception day of listed companies in Chongqing, Qin Fei, vice president and director of Zhifei Biotech, said that the company currently has 15 products on sale, including vaccines, biological products for tuberculosis, and drugs to treat metabolic diseases; currently, it has 42 independent research projects, including 29 preventive research projects in the reporting, clinical trials and registration stages, and 5 key treatment research projects in different clinical stages and applications for registration. The company is further promoting an internationalization strategy, promoting the export of products such as the quadrivalent influenza polysaccharide vaccine and overseas clinical work on Fuchs and Sonny's dysentery bivalent conjugate vaccine and the 26-valent pneumococcal conjugate vaccine.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.